

Press Release 04/10

March, 31 2010

Novalung GmbH continues expansion into Scandinavia

The world's first pumpless lung assist device, the iLA Membrane Ventilator[®], now exclusively available in Sweden and Norway through Vingmed Group.

Novalung GmbH, the German manufacturer of the world's leading therapeutic system for extrapulmonary lung support, has signed exclusive agreements with Vingmed Svenska AB and Vingmed AS for distribution of the iLA Membrane Ventilator[®] in Sweden and Norway, respectively.

Dr. Torsten Rinne, Medical Director of Novalung GmbH, noted: "We have seen the application of the iLA Membrane Ventilator extend increasingly to the support of patients with acute exacerbations of chronic lung disease (COPD). Thus, it is exciting to see how Vingmed has embraced the concept of helping these patients by combining extrapulmonary CO₂ removal with non-invasive ventilation as a way of limiting the negative effects that mechanical ventilation can have on their already damaged lungs."

Of 185 patients added to the company's iLA Patient Registry in 2009, almost 60% were patients with an acute worsening of a chronic disease (so called exacerbations). The Registry currently includes roughly 10% of the nearly 5,000 patients treated worldwide with the iLA Membrane Ventilator to date. Rinne comments: "Now that we have expanded the iLA Patient Registry to enable all of our customers to actively submit their clinical data, we look forward to a further significant increase in the data pool of COPD patients successfully treated with the iLA Membrane Ventilator. We hope that Vingmed's customers will be significant contributors to the Registry."

The Vingmed Group companies were chosen by Novalung due to their decades of experience with innovative medical procedures and their reputation for excellence in customer support. "The iLA Membrane Ventilator is a perfect addition to our current range of products" said Petter Solum of Vingmed AS.

The therapeutic aspects of using the iLA Membrane Ventilator and its relation to other extracorporeal therapies such as ECMO were presented to the participants of the annual meeting of the society of Swedish perfusionists (Swesect) in January 2010 in Visingsö, Sweden.

Press Release 04/10

March, 31 2010

You can download high-resolution pictures as well as the literature compendium on www.novalung.com or it will be sent on request via email.

Please send us a copy of your imprint.

Contact:

Franziska Preißing
Head of Marketing
franziska.preissing@novalung.com
Novalung GmbH
Egerten 3
D-74388 Talheim
Tel.: +49 7133 90 11 130
Fax: +49 7133 90 11 230
www.novalung.com

Press Release 04/10

March, 31 2010

Background information

iLA Membrane Ventilator[®]

The iLA Membrane Ventilator[®] is the world's first pumpless artificial lung assist device designed specifically to breathe outside the patient's body. The iLA Membrane Ventilator[®] supports the lung by removing carbon dioxide effectively and is therefore perfused by the human heart like a natural organ relieving the patient's lung as its gas exchange capacity is supported and the breathing work reduced. The patient's natural lung is given „Time to Heal“[®].

The iLA Membrane Ventilator[®] is connected non-surgically to a femoral (groin) artery and vein using two specially designed NovaPort[®] vascular access devices. The artificial lung itself measures only 14x14 cm. Inside, a hollow fibre membrane takes over the function of the pulmonary alveoli and thus supports or in some cases even replaces common mechanical ventilation. So-called “protective” ventilation strategies can now be pursued more aggressively;

In the scientific literature the iLA Membrane Ventilator[®] is also known as “pecla” (pumpless extracorporeal lung assist) or „AVCO2R“ (arterio-venous CO2 removal).

Novalung GmbH - Driver of a paradigm shift

Novalung's mission is to develop, produce and market innovative solutions for lung failure, including the world's first pumpless artificial lung assist device designed to breathe outside the patient's body. Founded in 2003, the German company operates on a highly international level focusing on the objective to replace damaging invasive mechanical ventilation.

Vingmed

The Vingmed group is one of the largest companies in Scandinavia for distribution and services of high quality medical technical products, with offices in Sweden, Norway and Denmark. The product programs are integrated for all three companies, but each company acts within its marketplace independently and, therefore, has its own local character.

The Vingmed Group focuses its business within the fields of cardiology, radiology, endoscopy, dialysis, intensive care, anesthesia, obstetrics, general-, vascular and thoracic surgery. The product range is evaluated with respect to high quality and competitiveness. When choosing suppliers, fast and reliable capacity of delivery and a high level of innovation and continuity are factors of great importance.